The European and American guidelines on dyslipidemia management overlap but also diverge in critical ways. A Johns Hopkins cardiologist highlights similarities and differences.
The SGLT-2 inhibitor canagliflozin was FDA-approved on September 30, 2019, to slow progression of diabetic kidney disease and reduce risk of heart failure hospitalization.
We take the long view on aspirin's history in this short slideshow. See how aspirin has shaped medicine from its discovery to the 18th century.
Take a look at the evolution of aspirin used in modern disease prevention to gain perspective on how more recent developments may affect your practice.
Lower bleeding rates but no increase in risk of death, MI, or stroke topped results reported from the TWIGHLIGHT study which compared ticagrelor monotherapy at 3 months post-PCI vs ticarelor plus aspirin.
Veterans who suffer from mental illness were found to be at an increased risk for major cardiovascular disease outcomes in a new study.
A recent study suggests blood pressure patterns later in life may be linked to dementia risk. Which patient cohort is at an increased risk?
What's your caffeine IQ? Test your knowledge on the latest caffeine research from its effect on cardiovascular disease to liver cancer with this brief quiz.
A large Swedish cohort study suggests that when it come to risk of atrial fibrillation, there are differences in the way women and men respond to endurance training.
Heavy smokers who quit remain at significantly increased CVD risk for up to 10 years or more, according to new research. Results suggest that current risk estimators may need revision.